Supernus Pharmaceuticals, Inc.

United Therapeutics Corporation

Supernus Pharmaceutcals, Inc.

Supermus Pharmaceuticals, Inc.

Tcd Royalty Sub, LLC

Padmanabh P Bhatt

Argaw Kidane

Likan Liang

Michael L Vieira

Kevin Edwards

Hua Wang

Austin B Huang

Henry H Flanner

Arash Raoufinia

Alexei Tchesnokov

David Dain

Jean-Philippe Taquet

Aleksandr Pechenov

Reynold Mariaux

Rong-Kun Chang

Sachin V Patel

Niraj Shah

Scott Ibrahim

Shimul K Ray

Jones W Bryan, Jr

Jones W Bryan

Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.

Modified release preparations containing oxcarbazepine and derivatives thereof

Formulations of molindone having superior stability and methods of administering same are provided. The formulations may be immediate, modified, or otherwise delayed release formulations of molindone.

Stabilized formulations of CNS compounds

Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Sustained-release formulations of topiramate

Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.

Formulations of viloxazine

Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

Methods for producing viloxazine salts and novel polymorphs thereof

An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

Osmotic drug delivery system

Growing community of inventors

Rockville, MD, United States of America

Padmanabh P Bhatt